The week in pharma: action, reaction and insight – week to March 15, 2024
By Barbara Obstoj-Cardwell. Editor
Among research news last week, Swiss clinical-stage biotech MoonLake Immunotherapies held an R&D day, when it presented new data on its pipeline, emphasizing the success of its sonelokimab in psoriatic arthritis. Also, US pharma giant Pfizer released Phase III data on its Adcetris for the treatment of B-cell lymphoma. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Mirum Pharmaceuticals’ Livmarli for the new indication of intrahepatic cholestasis (PFIC). Also of note, US pharma major ELI Lilly linked up with Amazon Pharmacy to make its products, including the new obesity drug Zepbound, available to patients. And the UK’s AstraZeneca announced a takeover bid for USA-based Amolyt Pharma for up to $1.05 billion.
MoonLake’s R&D day confirms SLK’s competitive profile in PsA & indication expansion plans
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze